Table 2 Clinicopathological characteristics of primary breast cancer patients in BCA cohort and HER2+ BCA cohort
Characteristic | n | BCA cohort, n (%) | n | HER2-amplified BCA cohort, n (%) |
|---|---|---|---|---|
Follow-up period for RFS (range) | Mean 10.4 yr. (1 mo.-22 yr.) | Mean 5.3 yr. (1 mo.-9 yr.) | ||
Age (range) | 308 | Median 61 yr. (32–93 yr.) | 177 | Median 60 yr. (29–91 yr.) |
< 50 years | 64 (20.8) | 36 (20.3) | ||
≥ 50 years | 244 (79.2) | 141 (79.7) | ||
HER2 status | 308 | 177 | ||
Positive | 47 (15.3) | 177 (100.0) | ||
Negative | 261 (84.7) | 0 (0.0) | ||
ER status | 307 | 177 | ||
Positive (≥10%) | 248 (80.8) | 113 (63.8) | ||
Negative (< 10%) | 59 (19.2) | 64 (36.2) | ||
PR status | 307 | 177 | ||
Positive (≥10%) | 201 (65.5) | 74 (41.8) | ||
Negative (< 10%) | 106 (34.5) | 103 (58.2) | ||
Triple negativity | 307 | 177 | ||
TNBC (HER2−/ER-/PR-) | 30 (9.8) | 0 (0.0) | ||
No TNBC | 277 (90.2) | 177 (100.0) | ||
Histological grade | 232 | 174 | ||
I-II | 179 (77.2) | 41 (23.6) | ||
III | 53 (22.8) | 133 (76.4) | ||
Ki67 proliferation index | 230 | 177 | ||
Low (< 20%) | 165 (71.7) | 33 (18.6) | ||
High (≥20%) | 65 (28.3) | 144 (81.4) | ||
Histological type | 304 | 168 | ||
Ductal | 173 (56.9) | 156 (92.9) | ||
Lobular | 131 (43.1) | 12 (7.1) | ||
Tumour size | 177 | 142 | ||
< 2 cm | 57 (32.2) | 68 (47.9) | ||
≥ 2 cm | 120 (67.8) | 74 (52.1) | ||
Tumour size | 308 | 172 | ||
pT1-pT2 | 282 (91.6) | 161 (93.6) | ||
pT3-pT4 | 26 (8.4) | 11 (6.4) | ||
Lymph nodal spread | 286 | 169 | ||
Positive pN+ | 114 (39.9) | 73 (43.2) | ||
Negative pN0 | 172 (60.1) | 96 (56.8) |